2017 Cryptosporidium Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan--Supplier Shares, Sales Forecasts, Innovative Technologies, Competitive Strategies, Emerging Opportunities
The report presents a detailed analysis of the Cryptosporidium diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cryptosporidium definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:
Contains 207 pages and 9 tables
- Hospitals
- Commercial/Private Labs
- Physician Offices
- Public Health Labs
Contains 207 pages and 9 tables
I. INTRODUCTION
II. WORLDWIDE TEST OVERVIEW, TECHNOLOGIES AND INSTRUMENTATION
A. Background, Diagnostic Tests, Vaccines and Drugs
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semiautomated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing
III. COUNTRY ANALYSES: SALES AND VOLUME FORECASTS
IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
VI. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VIII. COMPETITIVE ASSESSMENTS
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
BioRad
Cepheid
Diamedix/Erba
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic/GenProbe
ID Biomedical/GSK
Kreatech/Leica
Lonza
OrthoClinical Diagnostics
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens
Takara Bio
Thermo Fisher/Life Technology
Wallac/PE
Wako
II. WORLDWIDE TEST OVERVIEW, TECHNOLOGIES AND INSTRUMENTATION
A. Background, Diagnostic Tests, Vaccines and Drugs
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semiautomated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing
III. COUNTRY ANALYSES: SALES AND VOLUME FORECASTS
IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
VI. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VIII. COMPETITIVE ASSESSMENTS
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
BioRad
Cepheid
Diamedix/Erba
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic/GenProbe
ID Biomedical/GSK
Kreatech/Leica
Lonza
OrthoClinical Diagnostics
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens
Takara Bio
Thermo Fisher/Life Technology
Wallac/PE
Wako